<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176757</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c5-002</org_study_id>
    <nct_id>NCT04176757</nct_id>
  </id_info>
  <brief_title>A Study of ZN-c5 in Participants With Breast Cancer</brief_title>
  <official_title>A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeno Alpha Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeno Alpha Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects
      with breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corroborate the single agent Recommended Phase 2 Dose</measure>
    <time_frame>Throughout the study, an average of 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-biomarker relationship</measure>
    <time_frame>Throughout the study, an average of 15 months</time_frame>
    <description>Percentage positive of Immunohistochemistry (IHC) staining Estrogen Receptor (ER) as compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-biomarker relationship</measure>
    <time_frame>Throughout the study, an average of 15 months</time_frame>
    <description>Percentage positive of IHC staining Progesterone Receptor (PR) as compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-biomarker relationship</measure>
    <time_frame>Throughout the study, an average of 15 months</time_frame>
    <description>Percentage positive of IHC staining Ki-67 as compare to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ZN-c5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c5</intervention_name>
    <description>ZN-c5 study drug to be administered orally daily</description>
    <arm_group_label>ZN-c5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated ICF

          2. Age ≥ 18 years of age, either gender

          3. Females must be postmenopausal as defined by at least one of the following:

               1. Age ≥ 60 years;

               2. Age &lt; 60 years and cessation of regular menses for at least 12 consecutive months
                  with no alternative pathological or physiological cause; and serum estradiol and
                  follicle stimulating hormone levels within the local laboratory's normal
                  reference range for postmenopausal females;

               3. Documented bilateral oophorectomy

          4. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          6. Adequate organ function defined as follows:

               1. Hematologic: Platelets ≥ 100 × 109/L; Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil
                  count ≥ 1.5 × 109/L (without platelet transfusion or any hematopoietic growth
                  factors within previous 7 days of the hematologic laboratory values obtained at
                  the Screening Visit)

               2. Hepatic: Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT)

                  ≤ 2.5 × upper limit of normal (ULN); Total or conjugated bilirubin ≤ 1.5 × ULN

               3. Renal: Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min

        Exclusion Criteria:

          1. Major surgery, defined as any surgical procedure that involves general anesthesia and
             a significant incision (i.e., larger than what is required for placement of central
             venous access, percutaneous feeding tube, or biopsy) within 28 days of the first
             administration of study drug

          2. Treatment with another investigational drug or other intervention within 28 days
             before the first administration of study drug

          3. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral medication, including any unresolved nausea, vomiting, or
             diarrhea that is CTCAE v.5.0 Grade &gt; 1

          4. Myocardial infarction, symptomatic congestive heart failure (New York Heart
             Association Classification &gt; Class II), unstable angina, or serious uncontrolled
             cardiac arrhythmia within the last 6 months of study Day 1

          5. Uncontrolled inter-current illness

          6. History or evidence of clinically significant disorder, condition, or disease that, in
             the opinion of the Investigator would pose a risk to subject safety or interfere with
             the study evaluations, procedures, or completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mieke Ptaszynski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zeno Alpha Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mieke Ptaszynski, MD</last_name>
    <phone>8582634333</phone>
    <email>info@zenopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ. Clinical Centre of the Republic of Srpska Clinic of Oncology</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zivko Vranjes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre University of Sarajevo Oncolgy Clinic</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Semir Beslija, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

